Numerous studies have reported that PD-L1 expression in breast cancer or inflammatory cells (Ghebeh et al., 2006; Joneja et al., 2017) and PD-L1 expression of cancer cells have long been suggested as a reliable indicator for anti-PD1/PD-L1 drugs (Reck et al., 2016). Here, PDCD1 is linked to breast cancer.